Al­most half of all new drug ap­provals in 2018 re­lied on one clin­i­cal tri­al

Back in the 1970s and 1980s, the FDA made clear that at least two ad­e­quate and well-con­trolled stud­ies were nec­es­sary to es­tab­lish a new drug’s ef­fec­tive­ness, ex­cept in on­ly the rarest of cir­cum­stances.

Then in 1997, the Food and Drug Ad­min­is­tra­tion Mod­ern­iza­tion Act was passed, and Con­gress clar­i­fied that the FDA may con­sid­er “da­ta from one ad­e­quate and well-con­trolled clin­i­cal in­ves­ti­ga­tion and con­fir­ma­to­ry ev­i­dence” to ap­prove a new drug.

But in guid­ance from 1998, the FDA says that its re­liance on on­ly a sin­gle study “will gen­er­al­ly be lim­it­ed to sit­u­a­tions in which a tri­al has demon­strat­ed a clin­i­cal­ly mean­ing­ful ef­fect on mor­tal­i­ty, ir­re­versible mor­bid­i­ty, or pre­ven­tion of a dis­ease with po­ten­tial­ly se­ri­ous out­come and con­fir­ma­tion of the re­sult in a sec­ond tri­al would be prac­ti­cal­ly or eth­i­cal­ly im­pos­si­ble.”

The agency al­so ex­plains the per­sua­sive­ness of us­ing two stud­ies ver­sus one.

“Whether to re­ly on a sin­gle ad­e­quate and well-con­trolled study is in­evitably a mat­ter of judg­ment. A con­clu­sion based on two per­sua­sive stud­ies will al­ways be more se­cure than a con­clu­sion based on a sin­gle, com­pa­ra­bly per­sua­sive study,” the guid­ance notes.

Aaron Kessel­heim, pro­fes­sor of med­i­cine at Har­vard Med­ical School, told Fo­cus: “His­tor­i­cal­ly, the FDA guid­ance seemed to in­di­cate a pref­er­ence for two ad­e­quate and well-con­trolled tri­als since any sin­gle tri­al may be sub­ject to unan­tic­i­pat­ed or un­de­tect­ed sys­tem­at­ic bi­as­es. Of course, in some cas­es, the clin­i­cal need is high enough or the drug’s ef­fi­ca­cy is pow­er­ful enough that a sin­gle tri­al should be suf­fi­cient at least for ini­tial FDA ap­proval.

“But re­liance on a sin­gle tri­al—par­tic­u­lar­ly if that tri­al is sin­gle-arm, un­blind­ed, or eval­u­ates un­val­i­dat­ed sur­ro­gate mea­sures as the end­point—in­creas­es the risk to pa­tients that the drug may not work as well as ex­pect­ed (or, sep­a­rate­ly, may have safe­ty is­sues that out­weigh its ben­e­fits).  It would be use­ful to clear­ly in­form pa­tients when a new drug is ap­proved on the ba­sis of a sin­gle piv­otal tri­al and fol­low those drugs more close­ly af­ter ap­proval, with the idea of for­mal­ly re­vis­it­ing their ben­e­fit-risk bal­ance in the fu­ture. But stud­ies un­for­tu­nate­ly show that post­mar­ket re­quire­ments are of­ten not fol­lowed up com­plete­ly or in a time­ly fash­ion,” Kessel­heim added.

Ap­provals Based on a Sin­gle Tri­al

Ac­cord­ing to a 2014 JA­MA study, be­tween 2005 and 2012, the FDA ap­proved 188 nov­el ther­a­peu­tic agents for 206 in­di­ca­tions, and 74 in­di­ca­tions (36.8%) were ap­proved on the ba­sis of a sin­gle piv­otal tri­al.

Most re­cent­ly, IQVIA re­leased a re­port find­ing that 25 of 59 (42%) nov­el drugs ap­proved in 2018 were ap­proved on the ba­sis of on­ly one tri­al. And one out of eight ap­provals re­lied on­ly on Phase 1 or 2 tri­als, with no Phase 3 tri­als. But as in pre­vi­ous years, a large por­tion of the drugs re­ly­ing on on­ly one tri­al were new or­phan and can­cer drugs.

For in­stance, As­traZeneca’s or­phan drug Lu­mox­i­ti (mox­e­tu­momab pa­su­do­tox-td­fk) was ap­proved in Sep­tem­ber 2018 based on one tri­al of less than 100 pa­tients with a rare, slow-grow­ing blood can­cer. Stem­line Ther­a­peu­tics al­so won ap­proval in De­cem­ber 2018 for El­zon­ris (tagrax­o­fusp-erzx) to treat a rare, rapid­ly pro­gress­ing can­cer of the bone mar­row and blood af­ter con­duct­ing one tri­al of 94 pa­tients in the US.

Oth­er can­cer drugs, mean­while, won ap­proval af­ter larg­er sin­gle tri­als.

Pfiz­er’s Viz­im­pro (da­comi­tinib), for ex­am­ple, was ap­proved in Sep­tem­ber 2018 on the ba­sis of one clin­i­cal tri­al of 452 pa­tients with ad­vanced non-small cell lung can­cer in Asia. Ar­ray Bio­phar­ma’s Braftovi (en­co­rafenib) was ap­proved in June 2018 on ev­i­dence from one clin­i­cal tri­al of 383 pa­tients with BRAF V600 mu­ta­tion-pos­i­tive melanoma that was ad­vanced or could not be re­moved by surgery. The tri­al was con­duct­ed at 162 sites in Eu­rope, North Amer­i­ca and else­where.

And Ad­vanced Ac­cel­er­a­tor Ap­pli­ca­tions’ Lu­tathera (lutetium 177 dotate) was ap­proved based on one tri­al of 229 pa­tients with a spe­cif­ic type of rare tu­mor at 41 sites in Bel­gium, France, Ger­many, Italy, Por­tu­gal, Spain, UK and the US.

But not all the new drugs ap­proved in 2018 based on one clin­i­cal tri­al were can­cer treat­ments. For in­stance, Achao­gen’s Zem­dri (pla­zomicin) was ap­proved in June 2018 as a com­pli­cat­ed uri­nary tract in­fec­tion treat­ment based on one tri­al of 604 pa­tients in Eu­rope, the US and Mex­i­co.

Paratek Phar­ma­ceu­ti­cals al­so won ap­proval for its an­tibac­te­r­i­al med­i­cine Nuzyra (omada­cy­cline) in Oc­to­ber 2018 on the ba­sis of a sin­gle tri­al of 774 pa­tients with com­mu­ni­ty ac­quired bac­te­r­i­al pneu­mo­nia at 86 sites in Asia, Eu­rope, Is­rael, Latin Amer­i­ca, South Africa and the US.

But Kessel­heim said he does not think this is a re­cent shift to the use of one piv­otal tri­al, and he did not know if the 42% fig­ure from 2018 “is a sign that the num­ber is creep­ing high­er or just nor­mal year to year fluc­tu­a­tion.”

The IQVIA re­port al­so re­ports a slight uptick in the num­ber of piv­otal tri­als in 2018 be­ing ran­dom­ized con­trolled tri­als com­pared to pre­vi­ous years and that ac­tive con­trol arms were more com­mon in 2018 than re­cent past years.

The Chang­ing Land­scape of Re­search and De­vel­op­ment


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

An increase in demand of up to 79% for clinical trials in China has prompted Novotech the Asia-Pacific CRO to rapidly expand the China team, appointing expert local clinical executives to their Shanghai and Hong Kong offices. The company is planning to expand their team by 30% over the next quarter.

Novotech China has seen considerable demand recently which is borne out by research from GlobalData:
A global migration of clinical research is occurring from high-income countries to low and middle-income countries with emerging economies. Over the period 2017 to 2018, for example, the number of clinical trial sites opened by biotech companies in Asia-Pacific increased by 35% compared to 8% in the rest of the world, with growth as high as 79% in China.
Novotech CEO Dr John Moller said China offers the largest population in the world, rapid economic growth, and an increasing willingness by government to invest in research and development.
Novotech’s 23 years of experience working in the region means we are the ideal CRO partner for USA biotechs wanting to tap the research expertise and opportunities that China offers.
There are over 22,000 active investigators in Greater China, with about 5,000 investigators with experience on at least 3 studies (source GlobalData).

Daniel O'Day [via AP Images]

UP­DAT­ED: Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

Daniel O’Day is executing his first major development deal since taking over as CEO of Gilead $GILD. And he’s going in deep to ally himself with a longstanding partner.

O’Day announced today that he is spending $5 billion in cash to add new late-stage drugs to Gilead’s pipeline, picking up rights to Galapagos’ $GLPG Phase III IPF drug GLPG1690 alongside adoption of the biotech’s Phase IIb drug GLPG1972 for osteoarthritis. And Gilead is also putting billions more on the table for milestones, gaining options for everything else in Galapagos’ pipeline, with a shot at all rights outside of Europe.

Altogether, Gilead is gaining rights to 6 clinical-stage assets, 20 preclinical programs and everything else being hatched in translation.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,600+ biopharma pros reading Endpoints daily — and it's free.

Billing it­self as the first AI biotech to launch hu­man tri­als, Re­cur­sion adds $121M C round

Billing itself as the first AI biotech with programs in the clinic, Salt Lake City-based Recursion now has a $121 million bankroll to start gathering human data to see if it’s on the right track. 

“We’re trying to build this discovery engine,” Recursion CEO Chris Gibson tells me ahead of the C round news. “We now have the first two programs in the clinic.” And that, he adds, qualifies as a first for any AI establishment “that actually have something in the clinic.”

Hal Barron [File photo]

Hal Bar­ron's team at GSK scores a win with pos­i­tive Ze­ju­la PhI­II front­line study — now comes the hard part

Score one for Hal Barron and the new R&D team steering GlaxoSmithKline’s pipeline.

The pharma giant reported this morning that its recently acquired PARP, Zejula (niraparib), hit the primary endpoint on progression-free survival in a frontline maintenance setting for women suffering ovarian cancer — following chemo and regardless of their BRCA status.

GSK bet $5 billion on the Tesaro buyout primarily to get this drug, drawing the shaking heads of biopharma. Why pay a big premium for a drug like this when AstraZeneca was going from strength to strength with Lynparza, ran the argument, having won a hugely important accelerated approval to jump out ahead — way ahead — of the rest of the PARP players? Lynparza — now co-owned by a powerhouse cancer team at Merck — won the first approval in frontline maintenance in ovarian cancer.

FDA bats back As­traZeneca's SGLT di­a­betes drug for Type 1 di­a­betes — block­ing a class on safe­ty fears

The FDA has just fired its latest salvo at the SGLT class of diabetes drugs, blowing up some commercial opportunity at AstraZeneca as part of the collateral damage.

The pharma giant reported early Monday that the FDA has rejected its blockbuster drug Farxiga for Type 1 diabetes that can’t be controlled by insulin. And while the pharma giant maintained its usual grim silence in the face of a setback, this one should be easy to interpret.

Jonathan Symonds [via HSBC]

GSK to tap Jonathan Symonds as chair­man, lever­ag­ing Big Phar­ma ex­pe­ri­ence for con­sumer biz deal

Six months into its search for a new board chairman, GlaxoSmithKline has apparently found the perfect candidate in a seasoned executive groomed at AstraZeneca and Novartis. Jonathan Symonds is in the final stages of being appointed, Bloomberg reports.

In January Sir Philip Hampton announced his intention to step down and make way for a new leader to oversee the consumer health joint venture GSK is setting up with Pfizer. The deal — announced a month prior — would spin out the unit formerly headed by GSK CEO Emma Walmsley and merge it with the equivalent division at Pfizer to create a new entity to be listed separately.

UP­DAT­ED: Am­gen, No­var­tis scrap Alzheimer's stud­ies — is BACE fi­nal­ly dead or will Bio­gen and Ei­sai car­ry on?

The BACE theory of controlling Alzheimer’s died with failed pivotal projects at Merck, Eli Lilly and their partners at AstraZeneca. Now Amgen and Novartis have come along to bulldoze it under a mound of safety threats — leaving only Biogen and Eisai to carry on with a less than zero chance of success — with the notable addition that they may actually be doing harm to patients.

After the market closed Thursday, Amgen and Novartis announced that they were dumping two pivotal programs underway with the Banner Alzheimer’s Institute on their BACE drug CNP520 (umibecestat) after an independent review of the data indicated that patients’ cognitive abilities were actually worsening at a faster pace than the placebo arm.

Endpoints News

Basic subscription required

Unlock this story instantly and join 54,600+ biopharma pros reading Endpoints daily — and it's free.

Christi Shaw at JP Morgan 2019. Jeff Rumans for Endpoints News

Fresh out of Eli Lil­ly, Christi Shaw sur­faces as Daniel O'­Day's new CEO at CAR-T pi­o­neer Kite

Well, that didn’t take long. 

We found out Thursday evening that Christi Shaw has given up her top post as the head of the Bio-Medicines group at Eli Lilly for the helm at CAR-T pioneer Kite. New Gilead CEO Daniel O’Day, a Roche veteran, had made finding a Kite CEO a top priority on his arrival at Gilead. And he went right for a headliner.

O’Day was clearly excited about the coup.

“We conducted an extensive search for a new leader at Kite and we believe that Christi’s unique set of skills will allow us to continue to build on our leadership position in cell therapy,” he said in a prepared statement. “Christi’s vast experience across complex therapeutic areas, and particularly in oncology, will serve Kite very well. She is clearly a leader who will bring teams and individuals together and I am confident she will build upon the entrepreneurial spirit at Kite as we seek to help more people with cancer around the world.”

Christi Shaw at JP Morgan 2019. Jeff Rumans for Endpoints News

Eli Lil­ly's Christi Shaw bows out of top post at the Bio-Med­i­cines unit

Less than 3 years after Eli Lilly CEO David Ricks recruited Novartis vet Christi Shaw to run their big Bio-Medicines business, she’s out.

In a statement put out Thursday morning, Lilly said that Shaw’s last day will come at the end of August. Patrik Jonsson, currently president and general manager of Lilly Japan, will succeed Shaw once he gets the paperwork sorted out.

Lilly’s shares dropped 4% on the news.